Long-Term Debt: The sum of all long term debt fields.
enGene Therapeutics Inc (ENGN) had Long-Term Debt of $24.91M for the most recently reported fiscal quarter, ending 2026-04-30.
| Income Statement Financials | |
-- |
|
$-30.23M |
|
-- |
|
-- |
|
$31.97M |
|
$-31.97M |
|
$1.74M |
|
$-30.23M |
|
$-30.23M |
|
$-30.23M |
|
$-30.23M |
|
$-30.23M |
|
$-30.23M |
|
$-31.97M |
|
$-32.28M |
|
69.72M |
|
69.72M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$270.00M |
|
$2.33M |
|
$37.52M |
|
$307.52M |
|
$21.48M |
|
|
Long-Term Debt |
$24.91M |
$30.87M |
|
$52.36M |
|
$255.17M |
|
$255.17M |
|
$255.17M |
|
66.99M |
|
| Cash Flow Statement Financials | |
$-59.40M |
|
$-102.66M |
|
$141.73M |
|
$50.15M |
|
$29.83M |
|
$-20.32M |
|
$6.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.57 |
|
-- |
|
-- |
|
0.09 |
|
0.10 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-59.65M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.85% |
|
-11.85% |
|
-9.83% |
|
-10.79% |
|
$3.81 |
|
$-0.86 |
|
$-0.85 |
|